Your browser is no longer supported. Please, upgrade your browser.
Settings
GILD Gilead Sciences Inc. daily Stock Chart
GILD [NASD]
Gilead Sciences Inc.
IndexS&P 500 P/E6.93 EPS (ttm)11.69 Insider Own0.50% Shs Outstand1.34B Perf Week-5.14%
Market Cap108.80B Forward P/E6.59 EPS next Y12.29 Insider Trans-16.07% Shs Float1.32B Perf Month0.72%
Income17.34B PEG8.83 EPS next Q3.02 Inst Own81.90% Short Float1.68% Perf Quarter-19.56%
Sales32.84B P/S3.31 EPS this Y62.00% Inst Trans-0.20% Short Ratio2.19 Perf Half Y-11.18%
Book/sh9.69 P/B8.36 EPS next Y2.29% ROA36.60% Target Price110.37 Perf Year-25.30%
Cash/sh6.20 P/C13.08 EPS next 5Y0.79% ROE105.70% 52W Range77.92 - 118.14 Perf YTD-19.06%
Dividend1.88 P/FCF6.84 EPS past 5Y48.30% ROI45.90% 52W High-31.40% Beta1.11
Dividend %2.32% Quick Ratio1.60 Sales past 5Y32.60% Gross Margin86.90% 52W Low4.02% ATR2.25
Employees8000 Current Ratio1.80 Sales Q/Q2.60% Oper. Margin65.40% RSI (14)39.17 Volatility2.59% 2.23%
OptionableYes Debt/Eq1.70 EPS Q/Q-8.60% Profit Margin52.80% Rel Volume4.95 Prev Close81.05
ShortableYes LT Debt/Eq1.57 EarningsJul 25 AMC Payout14.30% Avg Volume10.16M Price81.05
Recom2.10 SMA20-5.08% SMA50-4.08% SMA200-12.59% Volume0 Change0.00%
Jul-26-16Reiterated RBC Capital Mkts Outperform $120 → $105
Jul-26-16Downgrade Needham Buy → Hold
Jun-01-16Initiated Gabelli & Co Buy $109
Apr-29-16Reiterated UBS Buy $130 → $118
Apr-29-16Downgrade Maxim Group Buy → Hold
Mar-16-16Reiterated Leerink Partners Outperform $130 → $127
Feb-25-16Initiated Citigroup Buy $110
Feb-12-16Reiterated Maxim Group Buy $137 → $115
Feb-03-16Reiterated RBC Capital Mkts Outperform $130 → $120
Feb-03-16Reiterated Piper Jaffray Overweight $134 → $114
Feb-03-16Reiterated Oppenheimer Outperform $124 → $120
Feb-03-16Reiterated Barclays Overweight $130 → $115
Feb-03-16Initiated Standpoint Research Buy $110
Jan-20-16Initiated Credit Suisse Outperform $125
Jan-15-16Upgrade BofA/Merrill Underperform → Neutral $107
Oct-28-15Reiterated Maxim Group Buy $129 → $137
Oct-20-15Reiterated Oppenheimer Outperform $120 → $124
Oct-02-15Downgrade Morgan Stanley Overweight → Equal-Weight
Sep-09-15Initiated Jefferies Hold
Jul-29-15Reiterated RBC Capital Mkts Outperform $120 → $130
Jul-27-16 08:23AM  Gilead Sciences, Inc. breached its 50 day moving average in a Bearish Manner : GILD-US : July 27, 2016
07:50AM  Major Biotechs See Increased Short Interest Bets at 24/7 Wall St.
Jul-26-16 07:01PM  Cramer: For Texas Instruments and Gilead, It's all About Trajectory -8.47%
05:30PM  Stocks finish mixed; Gilead and McDonald's fall as Texas Instruments jumps at Los Angeles Times
04:55PM  After GILD Earnings, Which Biomed Stock is Best Right Now?
04:42PM  Gilead Downgraded As Hepatitis C Declines Faster Than Expected
03:34PM  Harvoni Sales Declines Hurt Gilead Sciences Inc. in Q2 at Motley Fool
03:13PM  Gilead Sciences: Enough is Enough at Barrons.com
02:42PM  Stocks Trade Mixed as Crude Settles Under $43
02:16PM  Gilead plummets on weak outlook and downgrades at Silicon Beat
01:40PM  Gilead Sciences (GILD) Stock Plunges on Q2 Results, RBC Cuts Price Target
01:32PM  Stocks Lower As Selling Picks Up Late In Day; Restaurants Tumble
12:51PM  Jerome Dodson Comments on Gilead
12:33PM  Gilead Science's Falls Most in Almost Three Months
12:33PM  Gilead Science's Falls Most in Almost Three Months at Bloomberg
12:21PM  3 Key Takeaways Following Gilead Sciences' Second-Quarter Conference Call at Motley Fool
11:50AM  Why Analysts Are Thinking M&A Is Back on the Table for Gilead at 24/7 Wall St.
11:09AM  Bristol-Myers Squibbs 2Q16 Estimates: Virology Segment
11:07AM  Gliding's Not Enough for Gilead at Bloomberg
10:34AM  Why Gilead Can't Easily Copy Celgene's 'Partner Partner Partner' Deal-Making Playbook
10:07AM  Gilead (GILD) Beats on Q2 Earnings, Cuts 2016 Sales View
09:56AM  Stocks slightly higher as investors monitor company earnings
09:43AM  Earnings Reports Have Investors Abuzz About Gilead, Las Vegas Sands, 3 Other Stocks at Insider Monkey
09:39AM  Gilead Sciences: M&A Now? Please? at Barrons.com
09:30AM  The Zacks Analyst Blog Highlights: Texas Instruments, Gilead Sciences and Las Vegas Sands
09:06AM  Gilead Sciences Continues to Explore Opportunities
08:50AM  Top Analyst Upgrades and Downgrades: Gilead, Sprint, Starbucks, Southwest Air, Texas Instruments, Disney, Nordstrom and More at 24/7 Wall St.
08:24AM  Stock Futures Mixed as Fed Meets, Verizon and McDonald's Tumble
08:17AM  Stocks to Watch: July 26, 2016
07:39AM  Gilead Sciences downgraded by Needham
06:43AM  Wait On The DNC Before Going Long Biotech ETFs
06:17AM  Wait for Another 10% Drop In Gilead Before Buying
02:07AM  Edited Transcript of GILD earnings conference call or presentation 25-Jul-16 8:30pm GMT
01:04AM  [$$] More Patience Needed at Gilead at The Wall Street Journal
Jul-25-16 09:01PM  7 Key Figures From Gilead Sciences' Q2 Earnings at Motley Fool
08:30PM  Gilead Stock Falls 4% After Guidance Miss (GILD) at Investopedia
07:16PM  [$$] Gilead Sales of Hepatitis C Drugs Fall 19% at The Wall Street Journal
06:13PM  After-hours buzz: TXN, GILD, LVS & more at CNBC
06:02PM  [$$] More Patience Needed at Gilead at The Wall Street Journal
05:53PM  After The Close: Gilead, Las Vegas Sands, Texas Instruments Earnings
05:49PM  Q2 Earnings After the Bell Monday: TXN, GILD, LVS
05:39PM  Gilead (GILD) Stock Falls on Sales Miss and Lower 2016 Revenues Guidance
05:28PM  Gilead Trims Guidance But Beats Q2 Earnings Estimates
05:02PM  GILEAD SCIENCES INC Files SEC form 8-K/A, Results of Operations and Financial Condition, Financial Statements and Exh
04:37PM  Why Analysts Were Not Satisfied With Gilead Earnings at 24/7 Wall St.
04:30PM  Gilead Sciences Inc Earnings Call scheduled for 4:30 pm ET today
04:26PM  Gilead shares drop as drug maker cuts product sales outlook at MarketWatch
04:20PM  Gilead Lowers Product Sales Guidance on Weak Hepatitis C Sales
04:17PM  Gilead tops 2Q profit forecasts
04:15PM  GILEAD SCIENCES INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhib
04:10PM  Gilead Sciences Announces Third Quarter 2016 Dividend Business Wire
04:08PM  Gilead Sciences Announces Second Quarter 2016 Financial Results Business Wire
04:03PM  These 5 Healthcare Stocks Are Ridiculously Cheap at Motley Fool
12:06PM  Yee: Biotech stocks will outperform after election
12:00PM  Bracing for a 'bio-wreck'?
11:44AM  Gilead Sciences: What Do Analysts Recommend?
11:44AM  How Does Gilead Sciences Valuation Compare to Peers?
11:41AM  Limited gains seen for Gilead Sciences
11:15AM  Gilead Sciences Kicks Off 5 Big Pharma Earnings This Week
10:57AM  Gilead Sciences: Expect an Earnings Beat? at Barrons.com
09:05AM  What to Expect From Gilead Sciences Earnings at 24/7 Wall St.
08:53AM  The Market In 5 Minutes: Yahoo, Outerwall Highlight Merger Monday
08:30AM  Will Gilead Earnings Rebound this Quarter?
07:07AM  Q2 2016 Gilead Sciences Inc Earnings Release - After Market Close
05:12AM  AP Exclusive: Pricey drugs overwhelm Medicare safeguard
05:00AM  This Week Could Decide Whether Biotech ETFs' Rally Sizzles Or Fizzles
Jul-24-16 03:38PM  Scott Bauer's Gilead Sciences Trade
02:06PM  5 Reasons Biotech Stocks Are Smart Investments at Motley Fool
10:12AM  10 Must-See Earnings for the Coming Week at 24/7 Wall St.
07:41AM  3 Stocks That Turned $10,000 Into $1 Million at Motley Fool
Jul-23-16 07:01AM  I Just Bought These 4 Fast-Growing Biotech Stocks at Motley Fool
Jul-22-16 07:57PM  Why the Vanguard Growth Index Fund Has Done so Well in 2016
03:54PM  Options Insight: How to Play Gilead Sciences
03:54PM  Options Insight: How to Play Gilead Sciences at Bloomberg
02:08PM  Gilead Has a Problem. These Three Biotechs Could Be the Solution at Barrons.com
02:04PM  GILD Developing Next Generation HCV Drugs to Remain Competitive
01:38PM  Political Headwinds Dampen Gilead Sciences Outlook at Investopedia
01:06PM  These 4 Stocks Could See Negative Catalysts From Earnings -- but What Do the Charts Say?
12:38PM  Gilead Gets European CHMP's Positive Opinion On Its Type II Variation Application For Truvada
11:12AM  New York-Based Selz Capitals Top Picks for Q3; High-Yielding Macquarie Infrastructure Corp (MIC) Retains Top Spot at Insider Monkey
10:46AM  Gilead Sciences (GILD) Stock Drops Ahead of Q2 Earnings Report
09:53AM  Medical Stocks Reporting Early Next Week: GILD, LLY & More
07:17AM  European CHMP Adopts Positive Opinion on Gileads Type II Variation Application for Truvada® for Reducing the Risk of Sexually Acquired HIV Business Wire
12:16AM  Downtrend in GILDs Hepatitis C Drug Affecting Overall Revenues
Jul-21-16 11:33PM  Gilead Earnings on Tap: Can Hepatitis-C Recover? (GILD) at Investopedia
06:38PM  Gilead (GILD) Stock Likely to Beat This Earnings Season
04:30PM  Gileads Odefsey® (Emtricitabine, Rilpivirine, Tenofovir Alafenamide) Meets Primary 48-Week Objective in Two Phase 3b Studies Business Wire
02:08PM  Rallying biotech looks interesting for value investors, says top-rated analyst at CNBC
12:23PM  Gilead: As Earnings Loom, Dont Expect A Guidance Cut
12:00PM  Is biotech back?
11:54AM  Gilead: As Earnings Loom, Don't Expect A Guidance Cut at Forbes
10:42AM  3 Enormously Important Things You Won't See in Gilead Sciences' Q2 Results at Motley Fool
10:02AM  Biogen: CEO Departing; Is This Drug Maker In Play? at Barrons.com
07:00AM  The Incredible New Advances in the Fight Against HIV/AIDS at Fortune
Jul-20-16 03:42PM  Better Buy: Gilead Sciences Inc. vs. Amgen Inc. at Motley Fool
03:00PM  Six Major Biotech Acquisitions You Could See In 2016 (Part 1) at Forbes
11:54AM  How this biotech analyst thinks the presidential election will impact the overall health care space
09:47AM  Biotech: As Cheap as They Come at Barrons.com
09:30AM  Zacks.com featured highlights: Altria Group, Priceline Group, Zoetis, Gilead Sciences and Citrix Systems
08:36AM  Why Gilead Sciences (GILD) Might Surprise This Earnings Season
Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in areas of unmet medical needs in North America, South America, Europe, and the Asia-Pacific. The company's products include Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, Tybost, and Vitekta for the treatment of human immunodeficiency virus (HIV) infection in adults; and Harvoni, Sovaldi, Viread, and Hepsera products for the treatment of liver diseases. It also offers Zydelig, a PI3K delta inhibitor, in combination with rituximab, for the treatment of certain blood cancers; Letairis, an endothelin receptor antagonist for the treatment of pulmonary arterial hypertension; Ranexa, a tablet used for the treatment of chronic angina; Lexiscan/Rapiscan injection for use as a pharmacologic stress agent in radionuclide myocardial perfusion imaging; Cayston, an inhaled antibiotic for the treatment of respiratory systems in cystic fibrosis patients; and Tamiflu, an oral antiviral capsule for the treatment and prevention of influenza A and B. In addition, the company provides other products, such as AmBisome, an antifungal agent to treat serious invasive fungal infections; and Macugen, an anti-angiogenic oligonucleotide to treat neovascular age-related macular degeneration. Further, it has product candidates in various stages of development for the treatment of HIV/AIDS and liver diseases, such as hepatitis B virus and hepatitis C virus; inflammation/oncology; serious cardiovascular; and respiratory conditions, as well as diabetic nephropathy and ebola. The company markets its products through its commercial teams and/or in conjunction with third-party distributors and corporate partners. Gilead Sciences, Inc. has collaboration agreements with Bristol-Myers Squibb Company, Janssen R&D Ireland, Japan Tobacco Inc., and Galapagos NV. The company was founded in 1987 and is headquartered in Foster City, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
MILLIGAN JOHN FPresident and CEOJul 05Option Exercise16.40112,0001,836,2401,170,963Jul 07 02:50 PM
MILLIGAN JOHN FPresident and CEOJul 05Sale84.33112,0009,444,9211,058,963Jul 07 02:50 PM
Carter Paul RutherfordEVP Commercial OpsJul 01Option Exercise24.912,00049,81063,122Jul 06 01:26 PM
MARTIN JOHN CExecutive ChairmanJul 01Option Exercise16.40100,0001,639,5004,119,727Jul 06 01:28 PM
Carter Paul RutherfordEVP Commercial OpsJul 01Sale83.122,000166,25061,122Jul 06 01:26 PM
MARTIN JOHN CExecutive ChairmanJul 01Sale84.73100,0008,472,5234,019,727Jul 06 01:28 PM
MILLIGAN JOHN FPresident and CEOJun 06Option Exercise16.40112,0001,836,2401,170,963Jun 08 06:59 PM
MILLIGAN JOHN FPresident and CEOJun 06Sale86.94112,0009,736,7791,058,963Jun 08 06:59 PM
Carter Paul RutherfordEVP Commercial OpsJun 01Option Exercise24.912,00049,81063,122Jun 03 04:46 PM
MARTIN JOHN CExecutive ChairmanJun 01Option Exercise16.40100,0001,639,5004,119,727Jun 03 04:51 PM
Carter Paul RutherfordEVP Commercial OpsJun 01Sale87.022,000174,04061,122Jun 03 04:46 PM
MARTIN JOHN CExecutive ChairmanJun 01Sale86.72100,0008,671,9504,019,727Jun 03 04:51 PM
Carter Paul RutherfordEVP Commercial OpsMay 31Option Exercise33.8857,0921,934,021118,214Jun 02 04:35 PM
Carter Paul RutherfordEVP Commercial OpsMay 31Sale86.8557,0924,958,60061,122Jun 02 04:35 PM
Carter Paul RutherfordEVP Commercial OpsMay 02Option Exercise39.132,00078,25563,122May 04 04:23 PM
MARTIN JOHN CExecutive ChairmanMay 02Option Exercise16.40100,0001,639,5004,119,727May 04 02:44 PM
MILLIGAN JOHN FPresident and CEOMay 02Option Exercise16.40112,0001,836,2401,170,963May 04 02:49 PM
MARTIN JOHN CExecutive ChairmanMay 02Sale87.82100,0008,781,6944,019,727May 04 02:44 PM
MILLIGAN JOHN FPresident and CEOMay 02Sale87.71112,0009,823,9541,058,963May 04 02:49 PM
Carter Paul RutherfordEVP Commercial OpsMay 02Sale88.722,000177,44861,122May 04 04:23 PM
Alton Gregg HEVP, Corp & Med AffairsApr 19Option Exercise26.9935,874968,239177,964Apr 21 01:28 PM
Alton Gregg HEVP, Corp & Med AffairsApr 19Sale100.0140,0004,000,574137,964Apr 21 01:28 PM
MILLIGAN JOHN FPresident and CEOApr 04Option Exercise16.40112,0001,836,2401,170,963Apr 05 07:30 PM
MILLIGAN JOHN FPresident and CEOApr 04Sale94.59112,00010,593,9041,058,963Apr 05 07:30 PM
MARTIN JOHN CExecutive ChairmanApr 01Option Exercise16.40100,0001,639,5004,119,727Apr 05 07:49 PM
Carter Paul RutherfordEVP Commercial OpsApr 01Option Exercise24.912,00049,81063,122Apr 05 06:36 PM
Carter Paul RutherfordEVP Commercial OpsApr 01Sale91.342,000182,68061,122Apr 05 06:36 PM
Alton Gregg HEVP, Corp & Med AffairsApr 01Sale91.235,000456,158142,090Apr 05 07:45 PM
MARTIN JOHN CExecutive ChairmanApr 01Sale93.24100,0009,323,5074,019,727Apr 05 07:49 PM
Alton Gregg HEVP, Corp & Med AffairsMar 14Sale90.005,000450,000147,090Mar 15 07:31 PM
MARTIN JOHN CChairman and CEOMar 01Option Exercise16.40100,0001,639,5004,119,727Mar 03 02:47 PM
MILLIGAN JOHN FPresident, COO and DirectorMar 01Option Exercise16.40112,0001,836,2401,170,963Mar 03 02:54 PM
Carter Paul RutherfordEVP Commercial OpsMar 01Option Exercise24.912,00049,81063,122Mar 03 03:10 PM
Carter Paul RutherfordEVP Commercial OpsMar 01Sale87.902,000175,80061,122Mar 03 03:10 PM
MILLIGAN JOHN FPresident, COO and DirectorMar 01Sale87.79112,0009,832,9951,058,963Mar 03 02:54 PM
MARTIN JOHN CChairman and CEOMar 01Sale88.58100,0008,857,8544,019,727Mar 03 02:47 PM
Washington Robin LEVP, CFOFeb 16Sale90.726,250567,00084,688Feb 18 07:59 PM
MARTIN JOHN CChairman and CEOFeb 01Option Exercise16.40100,0001,639,5004,048,066Feb 03 05:43 PM
Carter Paul RutherfordEVP Commercial OpsFeb 01Option Exercise39.142,00078,27150,783Feb 03 05:42 PM
MARTIN JOHN CChairman and CEOFeb 01Sale83.42100,0008,342,4753,948,066Feb 03 05:43 PM
Carter Paul RutherfordEVP Commercial OpsFeb 01Sale82.322,000164,64048,783Feb 03 05:42 PM
Carter Paul RutherfordEVP Commercial OpsJan 04Option Exercise25.762,00051,52650,783Jan 06 05:08 PM
MARTIN JOHN CChairman and CEOJan 04Option Exercise16.40100,0001,639,5004,048,066Jan 06 05:21 PM
MARTIN JOHN CChairman and CEOJan 04Sale97.68100,0009,767,7083,948,066Jan 06 05:21 PM
Carter Paul RutherfordEVP Commercial OpsJan 04Sale99.202,000198,40048,783Jan 06 05:08 PM
BISCHOFBERGER NORBERT WEVP, R&D and CSODec 15Option Exercise21.9970,0001,539,562197,936Dec 17 03:40 PM
BISCHOFBERGER NORBERT WEVP, R&D and CSODec 15Sale102.4170,0007,168,741127,936Dec 17 03:40 PM
MILLIGAN JOHN FPresident and COODec 07Option Exercise14.50100,0001,450,2501,129,108Dec 09 02:14 PM
MILLIGAN JOHN FPresident and COODec 07Sale103.18100,00010,317,9771,029,108Dec 09 02:14 PM
Alton Gregg HEVP, Corp & Med AffairsDec 01Option Exercise24.3010,000242,950141,422Dec 03 01:57 PM
Carter Paul RutherfordEVP Commercial OpsDec 01Option Exercise26.992,00053,98050,783Dec 03 01:56 PM
MARTIN JOHN CChairman and CEODec 01Option Exercise14.50150,0002,175,3754,098,066Dec 03 01:57 PM
Carter Paul RutherfordEVP Commercial OpsDec 01Sale106.382,000212,76048,783Dec 03 01:56 PM
MARTIN JOHN CChairman and CEODec 01Sale105.82150,00015,873,4673,948,066Dec 03 01:57 PM
Alton Gregg HEVP, Corp & Med AffairsDec 01Sale106.0112,0001,272,159129,422Dec 03 01:57 PM
Cogan John FrancisDirectorNov 24Option Exercise20.7115,000310,57559,309Nov 25 02:21 PM
Cogan John FrancisDirectorNov 24Sale105.9515,0001,589,19044,309Nov 25 02:21 PM
Whitley Richard JamesDirectorNov 24Sale106.4816917,99530,719Nov 25 02:22 PM
Whitley Richard JamesDirectorNov 23Sale107.182,863306,84530,888Nov 25 02:22 PM
Whitley Richard JamesDirectorNov 20Sale106.995,514589,91733,751Nov 25 02:22 PM
BISCHOFBERGER NORBERT WEVP, R&D and CSONov 16Option Exercise23.7670,0001,662,850235,168Nov 18 12:32 PM
BISCHOFBERGER NORBERT WEVP, R&D and CSONov 16Sale102.6570,0007,185,419165,168Nov 18 12:32 PM
MILLIGAN JOHN FPresident and COONov 09Option Exercise14.50100,0001,450,2501,129,108Nov 12 01:01 PM
MILLIGAN JOHN FPresident and COONov 09Sale107.66100,00010,765,6441,029,108Nov 12 01:01 PM
Washington Robin LEVP, CFONov 05Option Exercise0.006,000033,724Nov 09 05:41 PM
MARTIN JOHN CChairman and CEONov 02Option Exercise14.50150,0002,175,3754,098,066Nov 04 01:23 PM
Alton Gregg HEVP, Corp & Med AffairsNov 02Option Exercise24.3010,000242,950143,422Nov 04 02:41 PM
Carter Paul RutherfordEVP Commercial OpsNov 02Sale108.362,000216,71248,783Nov 04 04:27 PM
Washington Robin LEVP, CFONov 02Sale109.466,250684,15088,046Nov 04 04:21 PM
Alton Gregg HEVP, Corp & Med AffairsNov 02Sale109.3812,0001,312,507131,422Nov 04 02:41 PM
MARTIN JOHN CChairman and CEONov 02Sale109.42150,00016,413,0263,948,066Nov 04 01:23 PM
Cogan John FrancisDirectorOct 27Option Exercise20.7115,000310,57559,309Oct 28 08:13 PM
Cogan John FrancisDirectorOct 27Sale110.0015,0001,650,00044,309Oct 28 08:13 PM
Cogan John FrancisDirectorOct 26Option Exercise20.7115,000310,57559,309Oct 27 03:09 PM
Cogan John FrancisDirectorOct 26Sale110.0015,0001,650,00044,309Oct 27 03:09 PM
Carter Paul RutherfordEVP Commercial OpsOct 26Sale110.061,500165,09248,783Oct 28 02:51 PM
BISCHOFBERGER NORBERT WEVP, R&D and CSOOct 15Option Exercise23.6070,0001,652,248235,168Oct 16 05:32 PM
BISCHOFBERGER NORBERT WEVP, R&D and CSOOct 15Sale100.0570,0007,003,220165,168Oct 16 05:32 PM
MILLIGAN JOHN FPresident and COOOct 07Option Exercise14.50100,0001,450,2501,129,108Oct 08 02:06 PM
MILLIGAN JOHN FPresident and COOOct 07Sale99.22100,0009,921,5241,029,108Oct 08 02:06 PM
Alton Gregg HEVP, Corp & Med AffairsOct 05Option Exercise24.305,000121,475138,422Oct 07 01:22 PM
Alton Gregg HEVP, Corp & Med AffairsOct 05Sale100.005,000500,000133,422Oct 07 01:22 PM
MARTIN JOHN CChairman and CEOOct 01Option Exercise14.50150,0002,175,3754,098,066Oct 05 01:28 PM
Alton Gregg HEVP, Corp & Med AffairsOct 01Option Exercise24.305,000121,475140,422Oct 05 02:13 PM
Alton Gregg HEVP, Corp & Med AffairsOct 01Sale97.287,000680,930133,422Oct 05 02:13 PM
MARTIN JOHN CChairman and CEOOct 01Sale97.48150,00014,622,2893,948,066Oct 05 01:28 PM
Carter Paul RutherfordEVP Commercial OpsOct 01Sale98.592,000197,18048,783Oct 05 04:26 PM
BISCHOFBERGER NORBERT WEVP, R&D and CSOSep 15Option Exercise23.6070,0001,652,000235,168Sep 17 04:26 PM
Cogan John FrancisDirectorSep 15Option Exercise20.7115,000310,57559,309Sep 17 03:54 PM
Alton Gregg HEVP, Corp & Med AffairsSep 15Option Exercise24.305,000121,475140,422Sep 17 03:55 PM
Alton Gregg HEVP, Corp & Med AffairsSep 15Sale110.005,000550,000135,422Sep 17 03:55 PM
BISCHOFBERGER NORBERT WEVP, R&D and CSOSep 15Sale110.7070,0007,749,195165,168Sep 17 04:26 PM
Cogan John FrancisDirectorSep 15Sale110.0015,0001,650,00044,309Sep 17 03:54 PM
MILLIGAN JOHN FPresident and COOSep 08Option Exercise14.50100,0001,450,2501,129,108Sep 10 02:57 PM
MILLIGAN JOHN FPresident and COOSep 08Sale103.39100,00010,338,7301,029,108Sep 10 02:57 PM
Washington Robin LEVP, CFOSep 02Sale102.206,250638,77894,296Sep 03 03:07 PM
Alton Gregg HEVP, Corp & Med AffairsSep 01Option Exercise24.2210,000242,208147,422Sep 03 03:06 PM
Alton Gregg HEVP, Corp & Med AffairsSep 01Sale102.7512,0001,233,008135,422Sep 03 03:06 PM
WILSON GAYLE EDirectorAug 28Option Exercise20.7180,0001,656,400122,769Aug 31 06:17 PM
WILSON GAYLE EDirectorAug 28Sale106.9621,0002,246,160101,769Aug 31 06:17 PM